EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

Exclusion Criteria

• •Primary central nervous system (CNS) malignancies that are symptomatic, untreated, or in need of curative treatment, or subjects with CNS metastases.
• •Uncontrolled co-morbidities.
• •Cerebrovascular event (stroke, transient ischemic attack, etc.) within 4 months prior to the signing of inform consent form.
• •In screening period male QTcF interval \>450 ms; Female QTcF interval \>470 ms (calculated by the Fridericia formula).
• •Left ventricular ejection fraction (LVEF) \< 50% during the screening period.
• •Diagnosis of immunodeficiency, or history or syndrome of active as well as former autoimmune disease with risk of relapse, or a disease requiring systemic steroid hormone or immunosuppressive drug therapy.
• •Subjects with a history of positive human immunodeficiency virus (HIV) test or acquired immunodeficiency syndrome (AIDS).
• •Co-infection HBV and HCV.
• •Presence of any active infection requiring systemic therapy.
• •Patients who are still on any other investigational medications treatment at the time of screening.
• •Previous treatment with cell therapy, tumor vaccines, cytokines, or growth factors for cancer control.
• •Patients with prior intolerance to tislelizumab resulting in permanent termination of tislelizumab.
• •History or presence of significant lung disease.